ArticleBMC surgery2026
Clinical characteristics and prognostic factors of severe intra-abdominal infection due to gastrointestinal perforation: a retrospective cohort study.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveGastrointestinal perforation is a medical emergency. We aimed to explore clinical characteristics and prognostic factors in patients with severe intra-abdominal infection due to gastrointestinal perforation.
methodsIn this retrospective cohort study, we reviewed patients diagnosed with severe intra-abdominal infection due to gastrointestinal perforation between January 2020 and January 2025. Demographics, clinical information, laboratory test results, management approach, 28-day mortality, and 180-day survival rate were recorded. Through regression probability analysis, multivariate logistic regression, Kaplan-Meier survival analysis, and Cox regression, we systematically analyzed patient clinical characteristics and determined the variables impacting their prognosis.
resultsA total of 108 eligible patients were included, with a 28-day mortality rate of 24.1% and a 180-day survival rate of 59.3%. Smoking history, diabetes, cardiovascular disease, rheumatic immune disease, malignant tumors, presence of elevated procalcitonin, the Acute Physiology and Chronic Health Evaluation II score, Mannheim Peritonitis Index score, low serum albumin and low prealbumin, infection from the stomach and duodenum, and fungal infection were independent risk factors while empirical use of antifungal drugs was associated with reduced 28-day mortality (all p < 0.05). Diabetes (p = 0.047), malignant tumors (p = 0.016), initial serum albumin level below 30 g/L, prealbumin level below 300 mg/L, infection source control time exceeding 12 h (p < 0.001), and enteral nutrition initiation time exceeding 6 days (p = 0.001) were independent risk factors for 180-day survival status. Compared with patients whose infection originated from the jejunum, ileum, cecum, or colon, infection from the stomach and duodenum was an independent risk factor for 180-day survival status.
conclusionPatients with severe intra-abdominal infection due to gastrointestinal perforation had poor prognosis. Multiple variables were identified to be associated with 28-day mortality and 180-day survival. Early infection source control, appropriate enteral nutrition initiation could improve prognosis.Early and timely empirical antifungal treatment in addition to other necessary interventions might be considered in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.